Satellos Bioscience Inc. experienced a significant drop in stock value, raising concerns among investors.
In yesterday's trading session, Satellos Bioscience Inc. (MSCL.TO) fell by 6.35%, closing at CA$10.77. This decline comes despite recent positive developments in their clinical trials.
Investor takeaway: Investors should remain cautious as the stock's recent performance raises questions about market confidence in Satellos's clinical progress.
Advertisement
Satellos Bioscience Inc.
MSCL.TO
MSCL.TO
Satellos Bioscience Inc.
WealthAwesomeMarket cap
$228.50M
52W high
$18.98
52W low
$7.56
1W change
-11.72%
Beta
1.15
Analyst Price Targets
Based on analyst covering MSCL · as of Sep 28, 2026
Wall Street analysts forecast MSCL stock price to rise 62.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$17.47
+62.2% Upside
Previously C$17.67 on Sep 17, 2026
Current Price
C$10.77
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSCL's historical volatility
30-Day Vol
53.4%
Annualized
90-Day Vol
71.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$9.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$10.15 | C$8.44 – C$12.20 |
| 60 trading days | C$9.56 | C$7.37 – C$12.41 |
| 90 trading days | C$9.01 | C$6.55 – C$12.39 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bull case
Satellos has made progress in clinical development, including receiving FDA clearance for their IND application for forazapadin. This could pave the way for future growth opportunities.
Bear case
The recent drop in stock price suggests that investors may be skeptical about the company's ability to meet its clinical promises or have concerns about its financial health.
Recent Performance
Satellos's stock performance yesterday was disappointing, with a drop of 6.35%. This decline raises questions about the market's confidence in the company's ongoing clinical trials and their potential outcomes.
Advertisement
Market Reaction
The market's reaction to Satellos's recent developments shows a level of skepticism. While the company has received FDA clearance for its IND application, investors may be weighing the risks of clinical trials against the backdrop of previous financial losses.
Looking Ahead
As Satellos continues to advance its clinical programs, investors should keep an eye on upcoming milestones and trial results. The company's ability to regain investor confidence will depend on demonstrating successful outcomes in its ongoing studies.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
